SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Lupin’s Bioresearch Centre

03 Apr 2019 Evaluate

United States Food and Drug Administration (USFDA) has successfully completed inspection at Lupin’s Bioresearch Centre (LBC) without any observations. This is the 5th successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility.

The company’s Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for company in Pune. This inspection also included review of studies done at the center's new site at Lupin Research Park, Pune.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2245.65 -132.25 (-5.56%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×